Successful Response to Intravitreal Faricimab Injections in a Case of Neovascular Age-Related Macular Degeneration in Vitrectomized Eyes

The half-life of anti-vascular endothelial growth factor (anti-VEGF) drugs shortens significantly after vitrectomy due to an increased intraocular pharmacokinetic clearance caused by the absence of the vitreous gel. This reduced half-life can limit the therapeutic effect of these intravitreal agents and complicate the management of conditions such as neovascular age-related macular degeneration (nAMD). We report a case of nAMD in a vitrectomized eye that showed inadequate response to both aflibercept and brolucizumab, but experienced effective suppression of exudation following intravitreal administration of faricimab. This case suggests that faricimab may offer a therapeutic benefit in managing exudative changes in vitrectomized eyes with nAMD.